EU Advances Tagrisso for Lung Cancer
EU recommends Tagrisso for EGFR-mutated NSCLC post-chemoradiation, citing significant PFS benefits in trials.
AstraZeneca's Tagrisso (osimertinib) has received a recommendation for approval in the European Union to treat adult patients with unresectable, EGFR-mutated non-small cell lung cancer (NSCLC) following platinum-based chemoradiation therapy. The approval is based on the LAURA Phase III trial, which showed Tagrisso reduced disease progression risk by 84%, extending median progression-free survival (PFS) to 39.1 months versus 5.6 months for placebo.
The trial highlights Tagrisso’s potential to address the unmet need in EGFR-mutated NSCLC, a disease affecting around 10-15% of NSCLC patients in Europe. While overall survival data remains immature, the results strengthen Tagrisso’s position as a critical therapy for EGFR-mutated lung cancer.
Already approved for similar indications in the U.S., Tagrisso’s safety profile remains consistent with no new concerns identified. Regulatory applications for this indication are under review in multiple countries, including China and Japan. The drug is currently approved in over 100 countries for various stages of EGFR-mutated NSCLC.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Curia New York reçoit une lettre d’avertissement de la FDA concernant des milliers d’injections chromatographiques non documentées
Ab Science révise les calendriers d'essais après trois inspections GCP
Discussion